149 related articles for article (PubMed ID: 2013210)
21. In vitro activity of BMY-28100, a new oral cephalosporin.
Eliopoulos GM; Reiszner E; Wennersten C; Moellering RC
Antimicrob Agents Chemother; 1987 Apr; 31(4):653-6. PubMed ID: 3496846
[TBL] [Abstract][Full Text] [Related]
22. Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin.
Neu HC; Chin NX; Labthavikul P
Antimicrob Agents Chemother; 1984 Aug; 26(2):174-80. PubMed ID: 6333207
[TBL] [Abstract][Full Text] [Related]
23. Ceftibuten: a review of antimicrobial activity, spectrum and other microbiologic features.
Jones RN
Pediatr Infect Dis J; 1995 Jul; 14(7 Suppl):S77-83. PubMed ID: 7567314
[TBL] [Abstract][Full Text] [Related]
24. In-vitro activity and beta-lactamase stability of LY163892.
Cao C; Chin NX; Neu HC
J Antimicrob Chemother; 1988 Aug; 22(2):155-65. PubMed ID: 3263352
[TBL] [Abstract][Full Text] [Related]
25. Ceftibuten: minimal inhibitory concentrations, postantibiotic effect and beta-lactamase stability--a rationale for dosing programs.
Neu HC
Pediatr Infect Dis J; 1995 Jul; 14(7 Suppl):S88-92. PubMed ID: 7567316
[TBL] [Abstract][Full Text] [Related]
26. In vitro susceptibility of Helicobacter pylori to the new oral cephalosporins cefpodoxime, ceftibuten and cefixime.
Westblom TU; Gudipati S; Midkiff BR
Eur J Clin Microbiol Infect Dis; 1990 Sep; 9(9):691-3. PubMed ID: 2226500
[TBL] [Abstract][Full Text] [Related]
27. BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolates.
Jones RN; Barry AL
Diagn Microbiol Infect Dis; 1988 Jan; 9(1):11-26. PubMed ID: 3259489
[TBL] [Abstract][Full Text] [Related]
28. The in-vitro activity of cefpodoxime: a comparison with other oral cephalosporins.
Wise R; Andrews JM; Ashby JP; Thornber D
J Antimicrob Chemother; 1990 Apr; 25(4):541-50. PubMed ID: 2351624
[TBL] [Abstract][Full Text] [Related]
29. Antimicrobial effects of the combination of ceftibuten and an orally absorbed penem SCH 29482.
Chin NX; Gu JW; Neu HC
Diagn Microbiol Infect Dis; 1991; 14(1):79-83. PubMed ID: 2013213
[TBL] [Abstract][Full Text] [Related]
30. Probability of achieving requisite pharmacodynamic exposure for oral beta-lactam regimens against Haemophilus influenzae in children.
Pichichero ME; Doern GV; Kuti JL; Nicolau DP
Paediatr Drugs; 2008; 10(6):391-7. PubMed ID: 18998749
[TBL] [Abstract][Full Text] [Related]
31. Antibacterial activity and beta-lactamase stability of MDL 19,592, an oral cephalosporin.
Yu KW; Neu HC
Diagn Microbiol Infect Dis; 1989; 12(5):441-3. PubMed ID: 2515027
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of cefcanel versus other oral cephalosporins.
Chin NX; Gu JW; Neu HC
Eur J Clin Microbiol Infect Dis; 1991 Aug; 10(8):676-82. PubMed ID: 1748125
[TBL] [Abstract][Full Text] [Related]
33. Ceftibuten (7432-S, SCH 39720): comparative antimicrobial activity against 4735 clinical isolates, beta-lactamase stability and broth microdilution quality control guidelines.
Jones RN; Barry AL
Eur J Clin Microbiol Infect Dis; 1988 Dec; 7(6):802-7. PubMed ID: 3145869
[TBL] [Abstract][Full Text] [Related]
34. RU 29 246, the active compound of the cephalosporin-prodrug-ester HR 916. I. Antibacterial activity in vitro.
Bauernfeind A; Jungwirth R; Eberlein E; Klesel N; Adam F; Isert D; Limbert M; Markus A; Schrinner E; Seibert G
J Antibiot (Tokyo); 1992 Apr; 45(4):505-20. PubMed ID: 1592683
[TBL] [Abstract][Full Text] [Related]
35. [In vitro effect of cefixime against Haemophilus influenzae].
Dabernat H; Delmas C
Presse Med; 1989 Oct; 18(32):1551-2. PubMed ID: 2530529
[TBL] [Abstract][Full Text] [Related]
36. In-vitro activity and beta-lactamase stability of SR 44337, a new long acting cephalosporin.
Cooper MA; Andrews JM; Baldwin DR; Thornber D; Wise R
J Antimicrob Chemother; 1991 Aug; 28(2):229-37. PubMed ID: 1778854
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin.
Briggs BM; Jones RN; Erwin ME; Barrett MS; Johnson DM
Diagn Microbiol Infect Dis; 1991; 14(5):425-34. PubMed ID: 1797457
[TBL] [Abstract][Full Text] [Related]
38. [A comparative study of antibacterial activity of ceftibuten, ceftazidime, cefuroxime and ampicillin against clinical isolates].
Ergova R; K'oleian E; Kharalambieva Ia; Mitov I; Docheva Iu
Vutr Boles; 2000; 32(1):13-7. PubMed ID: 11195191
[TBL] [Abstract][Full Text] [Related]
39. Cefdinir: in vitro activity study and effect of human serum.
García-Rodríguez JA; Trujillano-Martín I; García-Sánchez JE
Drugs Exp Clin Res; 1993; 19(2):51-8. PubMed ID: 8223142
[TBL] [Abstract][Full Text] [Related]
40. [In vitro antibacterial activity of a new oral cephalosporin, ceftibuten. Results of a multicenter study].
Soussy CJ; Meyran M; Chanal M; Reverdy ME; Kitzis MD; Derlot E
Pathol Biol (Paris); 1991 May; 39(5):396-402. PubMed ID: 1909017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
